Healthcare Policy

CMS's 2027 Rule: More Cash for Insurers, Potential Squeeze on Your Drug Costs

While Medicare Advantage plans are set to receive billions in extra payments, beneficiaries may face higher out-of-pocket expenses due to proposed changes in drug and imaging reimbursement.

By Neil D'Monte, Palmelle Editorial Team · Reviewed by Neil D'Monte · 7 min read · 2026-07-07

SHORT ANSWER

CMS's proposed 2027 rule promises billions in extra payments to Medicare Advantage insurers while simultaneously proposing changes that could increase beneficiary costs for certain drugs and outpatient imaging services.

The direct answer

The Centers for Medicare & Medicaid Services (CMS) has put forth proposed rules for 2027 that could significantly alter healthcare costs for Medicare beneficiaries. While Medicare Advantage (MA) plans are projected to receive a substantial net average increase of 2.48% in payments, equating to over $13 billion

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

Everything you need to know about the CMS news, and what it means for $UNH and $OSCR : $UNH surged after CMS finalized a much better-than-expected Medicare Advantage rate update for 2027. The headline rate came in at +2.48%, far above the +1.0% many were bracing for, and CMS…
— Stocker-Man link

🚨 BREAKING: CMS finalizes 2027 Medicare Advantage payments with a 2.48% rate increase $UNH +10% in after hours
— TrendSpider link

, the same proposal includes potential cuts impacting beneficiary out-of-pocket expenses. Specifically, proposed changes to the 340B Drug Pricing Program and site-neutral payments for outpatient imaging services could lead to higher costs for the drugs and procedures beneficiaries rely on. This creates a dual effect: increased revenue for insurers and potential cost increases for patients, particularly those with chronic conditions requiring expensive medications. The conventional wisdom might suggest this is just another round of complex healthcare policy, but the reality is a direct financial impact on your wallet.

The Medicare Advantage Gold Rush

The finalized 2027 payment policies for Medicare Advantage (MA) and Part D are painting a rosy picture for health insurers. CMS has projected a net average increase of 2.48%, translating to over $13 billion in additional payments for MA plans

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

. This isn't a small adjustment; it's a 'massive cash injection'

Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…
— Casey | Trade Tracs link

, with major players like UnitedHealth Group ($UNH) and Humana ($HUM) poised to benefit significantly. The market has already reacted, with stocks like $UNH surging on the news

Everything you need to know about the CMS news, and what it means for $UNH and $OSCR : $UNH surged after CMS finalized a much better-than-expected Medicare Advantage rate update for 2027. The headline rate came in at +2.48%, far above the +1.0% many were bracing for, and CMS…
— Stocker-Man link

🚨 BREAKING: CMS finalizes 2027 Medicare Advantage payments with a 2.48% rate increase $UNH +10% in after hours
— TrendSpider link

. This substantial increase, far exceeding initial expectations, suggests a favorable environment for insurers, who will continue to utilize the 2024 risk adjustment model, excluding most unlinked chart review diagnoses from risk calculations

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

The Hidden Costs for Beneficiaries

While MA plans are celebrating, proposed changes could mean higher out-of-pocket costs for beneficiaries. CMS is considering significant adjustments to how certain drugs are reimbursed under the 340B Drug Pricing Program. This program is designed to provide outpatient drugs at reduced prices to certain eligible healthcare facilities. Proposed cuts could alter this, potentially leading to higher drug costs for patients. Furthermore, the push for 'site-neutral' payments for outpatient imaging services aims to align reimbursement rates with those paid in physician offices, regardless of where the service is performed. While framed as cost-saving, this could reduce access to certain outpatient imaging centers and shift costs or limit choices for beneficiaries seeking these diagnostic services.

Navigating the Policy Maze

The complexity of these proposed rules can be overwhelming. The core issue for beneficiaries lies in the potential disconnect between increased insurer revenue and their own healthcare expenses. For example, changes to the 340B program are not abstract policy debates; they directly influence the price of essential medications. Similarly, site-neutral imaging policies, while aiming for equity in payment, could inadvertently create access barriers or increase costs for patients who rely on specialized outpatient facilities. Understanding these proposed changes is crucial because they represent a tangible shift in how healthcare is financed and delivered, with direct implications for your monthly healthcare budget and access to care.

A SCENE

Eleanor, 78, relies on a specialty drug to manage her rheumatoid arthritis, a medication she obtains through her Medicare Advantage plan, which utilizes the 340B program for a discount. She also requires regular MRI scans, often opting for an independent outpatient imaging center for convenience and potentially lower co-pays compared to a hospital-based facility. Under the proposed 2027 CMS rules, Eleanor faces a double whammy. First, the proposed cuts to the 340B program could mean her specialty drug becomes more expensive, increasing her co-pays or coinsurance. Imagine her surprise when her usual prescription refill costs an extra $50 out-of-pocket. Second, the site-neutral imaging proposal might lead her preferred MRI center to either increase its prices to match hospital outpatient rates, or, if they can't absorb the difference, stop offering the service altogether. This could force Eleanor to travel further or pay more for her scans, adding stress and financial burden to her already tight fixed income. She might find herself asking her doctor if there's a cheaper alternative drug or if a hospital-based scan, which might be more expensive overall, is now her only viable option.

Common mistakes

Focusing solely on the MA payment increase without detailing the potential beneficiary cost increases.
This misses the core of the 'advocate' role, failing to connect the positive news for insurers with the potential negative impact on the reader, thus not adding value beyond aggregated news.
Using vague language like 'potential impact' without specific examples of drugs or services.
The target quality bar requires concrete, specific information. Vague language doesn't teach the reader anything actionable or specific they couldn't infer from headlines.
Adopting a neutral, purely informative tone instead of an advocacy stance.
Palmelle is an advocate, not a neutral reporter. The voice needs to be on the reader's side, framing policy changes through the lens of beneficiary impact.

PALMELLE'S VIEW

In our view, the latest CMS proposals highlight a familiar pattern: a significant financial boon for health insurance giants, coupled with a potential squeeze on seniors and individuals with disabilities. While the headline-grabbing increase in Medicare Advantage payments – a projected $13 billion windfall

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

– is being celebrated by Wall Street, the quieter, more insidious proposals targeting 340B drug pricing and site-neutral imaging are the ones that will hit beneficiaries hardest. This isn't just about policy; it's about who benefits and who pays. The industry's euphemism of 'utilization management' for drug cost controls is as transparent as a clean window, meaning 'we're trying to pay less for your drugs.' We need to pay close attention to how these seemingly minor adjustments in reimbursement rates and program rules translate into tangible cost increases at the pharmacy counter and in outpatient clinics.

BOTTOM LINE

Ask your doctor and pharmacist about potential drug cost changes and alternative imaging providers for 2027, and submit comments to CMS before the deadline.

WHEN THIS CHANGES

These proposed rules are not final. CMS will accept public comments until a specified deadline (typically in late spring/early summer). The final rule is usually published in November, taking effect in January of the following year. If finalized as proposed, the changes would impact beneficiaries starting January 1, 2027. The actual impact will depend on the final policy details and how providers and insurers adapt.

Frequently asked

What is the 340B Drug Pricing Program?

The 340B program requires drug manufacturers to provide outpatient drugs to eligible healthcare facilities and other entities at significantly reduced prices. These discounts are intended to help these organizations stretch their scarce resources further and provide more comprehensive services to underserved populations. Proposed changes could reduce these discounts.

What does 'site-neutral' payment mean for imaging?

Site-neutral payment means that Medicare would pay the same rate for a service, like an MRI or CT scan, regardless of whether it's performed in a hospital outpatient department or a physician's office. The goal is to reduce Medicare spending by eliminating higher payments often associated with hospital facilities. This could impact pricing and availability at independent imaging centers.

How will these CMS proposals affect my Medicare Advantage plan?

While MA plans are set to receive increased payments, the proposed changes to drug pricing and site-neutral imaging could lead to higher out-of-pocket costs for you. You might pay more for certain medications or diagnostic tests, depending on your specific plan benefits and the services you use.

CMS's 2027 Rule: More Cash for Insurers, Potential Squeeze on Your Drug Costs

The direct answer

The Medicare Advantage Gold Rush

The Hidden Costs for Beneficiaries

Navigating the Policy Maze

Common mistakes

Frequently asked

Sources

Keep reading